Efficacy and Safety of Bevacizumab for Treating Glioblastoma: A Systematic Review and Meta-Analysis of Phase II and III Randomized Controlled Trials

References

• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, National Cancer Institute of Canada Clinical Trials Group, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013; 310(17):1842–1850. doi:10.1001/jama.2013.280319.
   PubMed Web of Science ®Google Scholar
• Field KM, Jordan JT, Wen PY, Rosenthal MA, Reardon DA. Bevacizumab and glioblastoma: scientific review, newly reported updates, and ongoing controversies. Cancer. 2015;121(7):997–1007.
   PubMed Web of Science ®Google Scholar
• Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas. Curr Oncol Rep. 2010;12(1):26–33. doi:10.1007/s11912-009-0077-4.
   PubMed Web of Science ®Google Scholar
• Jakobsen JN, Hasselbalch B, Stockhausen M-T, Lassen U, Poulsen HS. Irinotecan and bevacizumab in recurrent glioblastoma multiforme. Expert Opin Pharmacother. 2011;12(5):825–833.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–1012.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. doi:10.1016/0197-2456(95)00134-4.
   PubMedGoogle Scholar
• Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–722.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708. doi:10.1056/NEJMoa1308573.
   PubMed Web of Science ®Google Scholar
• Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, et al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377(20):1954–1963.
   PubMed Web of Science ®Google Scholar
• Taal W, Oosterkamp HM, Walenkamp AME, Dubbink HJ, Beerepoot LV, Hanse MCJ, et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol. 2014;15(9):943–953. doi:10.1016/S1470-2045(14)70314-6.
   PubMed Web of Science ®Google Scholar
• Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, et al. A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma. Oncologist. 2019; 24(4):521–528.
   PubMed Web of Science ®Google Scholar
• Wirsching H-G, Tabatabai G, Roelcke U, Hottinger AF, Jörger F, Schmid A, et al. Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Ann Oncol. 2018;29(6):1423–1430.
   PubMed Web of Science ®Google Scholar
• Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(7):1003–1010.
   PubMed Web of Science ®Google Scholar
• Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, et al. Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma. Clin Cancer Res. 2021;27(4):1048–1057.
   PubMed Web of Science ®Google Scholar
• Chauffert B, Feuvret L, Bonnetain F, Taillandier L, Frappaz D, Taillia H, et al. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF. Ann Oncol. 2014;25(7):1442–1447.
   PubMed Web of Science ®Google Scholar
• Carlson JA, Reddy K, Gaspar LE, Ney D, Kavanagh BD, Damek D, et al. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. J Neurooncol. 2015;123(2):251–257.
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, et al. Bevacizumab plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: the randomized GLARIUS trial. JCO. 2016;34(14):1611–1619. doi:10.1200/JCO.2015.63.4691.
   PubMed Web of Science ®Google Scholar
• He Y, Roos WP, Wu Q, Hofmann TG, Kaina B. The SIAH1-HIPK2-p53ser46 damage response pathway is involved in temozolomide-induced glioblastoma cell death. Mol Cancer Res. 2019;17(5):1129–1141.
   PubMed Web of Science ®Google Scholar
• Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol. 2001;2(9):552–560.
   PubMed Web of Science ®Google Scholar
• Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M, et al. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020;70(4):299–312.
   PubMed Web of Science ®Google Scholar
• Fisher JP, Adamson DC. Current FDA-approved therapies for high-grade malignant gliomas. Biomedicines. 2021; 9(3):324. doi:10.3390/biomedicines9030324.
   PubMed Web of Science ®Google Scholar
• Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011;117(21):4939–4947.
   PubMed Web of Science ®Google Scholar
• Weathers S-P, Han X, Liu DD, Conrad CA, Gilbert MR, Loghin ME, et al. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma. J Neurooncol. 2016;129(3):487–494.
   PubMed Web of Science ®Google Scholar
• Wenger KJ, Wagner M, You S-J, Franz K, Harter PN, Burger MC, et al. Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine. Oncol Lett. 2017;4(1):1141–1146.
   Google Scholar
• Du C, Ren J, Zhang R, Xin T, Li Z, Zhang Z, et al. Effect of bevacizumab plus temozolomide-radiotherapy for newly diagnosed glioblastoma with different MGMT Methylation Status: a meta-analysis of clinical trials. Med Sci Monit. 2016;22:3486–3492.
   PubMed Web of Science ®Google Scholar
• Chen Z, Xu N, Zhao C, Xue T, Wu X, Wang Z, et al. Bevacizumab combined with chemotherapy vs single-agent therapy in recurrent glioblastoma: evidence from randomized controlled trials. Cancer Manag Res. 2018;10:2193–2205.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda DG, Cohen KS, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83–95.
   PubMed Web of Science ®Google Scholar
• Jahnke K, Muldoon LL, Varallyay CG, Lewin SJ, Kraemer DF, Neuwelt EA, et al. Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model. Neuro Oncol. 2009;11(2):142–150. doi:10.1215/15228517-2008-077.
   PubMed Web of Science ®Google Scholar
• Kamiya-Matsuoka C, Hamza MA, de Groot JF. Impact of adverse events of bevacizumab on survival outcomes of patients with recurrent glioblastoma. J Clin Neurosci. 2020;74:36–40.
   PubMed Web of Science ®Google Scholar
• Qi W-X, Fu S, Zhang Q, Guo X-M. Bevacizumab increases the risk of infections in cancer patients: a systematic review and pooled analysis of 41 randomized controlled trials. Crit Rev Oncol Hematol. 2015;94(3):323–336.
   PubMed Web of Science ®Google Scholar
• Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871–882.
   PubMed Web of Science ®Google Scholar
• Song J, Xue Y-Q, Zhao M-M, Xu P. Effectiveness of lomustine and bevacizumab in progressive glioblastoma: a meta-analysis. Onco Targets Ther. 2018;11:3435–3439.
   PubMed Web of Science ®Google Scholar
• Kaka N, Hafazalla K, Samawi H, Simpkin A, Perry J, Sahgal A, et al. Progression-free but no overall survival benefit for adult patients with bevacizumab therapy for the treatment of newly diagnosed glioblastoma: a systematic review and meta-analysis. Cancers. 2019;11(11):1723–1284. doi:10.3390/cancers11111723.
   PubMed Web of Science ®Google Scholar
• Zhang T, Xin Q, Kang JM. Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2021;25(21):6480–6491. doi:10.26355/eurrev_202111_27092.
   PubMed Web of Science ®Google Scholar
• Ren X, Ai D, Li T, Xia L, Sun L. Effectiveness of lomustine combined with bevacizumab in glioblastoma: a meta-analysis. Front Neurol. 2020;11:603947.
   PubMed Web of Science ®Google Scholar
• Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S, et al. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw. 2011;9(4):403–407.
   PubMed Web of Science ®Google Scholar
• Fu P, He Y-S, Huang Q, Ding T, Cen Y-C, Zhao H-Y, et al. Bevacizumab treatment for newly diagnosed glioblastoma: systematic review and meta-analysis of clinical trials. Mol Clin Oncol. 2016;4(5):833–838.
   PubMedGoogle Scholar
• Yang S-B, Gao K-D, Jiang T, Cheng S-J, Li W-B. Bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis of randomized controlled trials. Oncotarget. 2017;8(34):57337–57344.
   PubMedGoogle Scholar
• Liao KL, Huang S, Wu YP. The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis. Onco Targets Ther. 2018;11:3513–3520.
   PubMed Web of Science ®Google Scholar